Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
01.04. | Climb Bio, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
25.03. | Climb Bio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
25.03. | Climb Bio, Inc.: Climb Bio Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Updates | 523 | GlobeNewswire (Europe) | Received Clearance from the U.S. Food and Drug Administration (FDA) for Clinical Trials of Budoprutug in Primary Membranous Nephropathy (pMN), Immune Thrombocytopenia (ITP), and Systemic Lupus Erythematosus... ► Artikel lesen | |
CLIMB BIO Aktie jetzt für 0€ handeln | |||||
25.03. | Climb Bio, Inc. - 10-K, Annual Report | 2 | SEC Filings | ||
24.02. | Climb Bio, Inc.: Climb Bio Appoints Perrin Wilson, Ph.D., as Chief Business Officer | 324 | GlobeNewswire (Europe) | WELLESLEY HILLS, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM) announced today the appointment of Perrin Wilson, Ph.D. as Chief Business Officer. Dr. Wilson is an accomplished... ► Artikel lesen | |
10.01. | Climb Bio enters licensing deal with Mabworks for CLYM116 development | 1 | Pharmaceutical Technology | ||
10.01. | Climb Bio, Inc. - 8-K, Current Report | - | SEC Filings | ||
09.01. | Climb Bio, Inc.: Climb Bio Expands Pipeline Through an Exclusive License to Develop and Commercialize an Antibody Targeting the APRIL Pathway for IgA Nephropathy | 194 | GlobeNewswire (Europe) | Transaction Expands Climb Bio's Pipeline of B-cell Targeted Therapeutics to Address Immune-mediated Diseases New Program is a Highly Potent, Fc-engineered anti-APRIL Monoclonal Antibody Specifically... ► Artikel lesen | |
19.12.24 | Climb Bio, Inc.: Climb Bio to be Added to the Nasdaq Biotechnology Index | 116 | GlobeNewswire (Europe) | WELLESLEY HILLS, Mass., Dec. 19, 2024 (GLOBE NEWSWIRE) -- December 19, 2024 - Climb Bio, Inc. (Nasdaq: CLYM) today announced that the company will be added to the NASDAQ Biotech Index (Nasdaq: NBI)... ► Artikel lesen | |
11.11.24 | Climb Bio names Douglas Williams as chair | 1 | Seeking Alpha | ||
11.11.24 | Climb Bio, Inc.: Climb Bio Appoints Douglas E. Williams, Ph.D., as Chair of the Board | 1 | GlobeNewswire (USA) | ||
24.10.24 | Woodforest Acceptance Solutions Partners With Clym to Enhance Website Accessibility and Compliance With Consumer Privacy Regulations | 298 | ACCESS Newswire | Woodforest Acceptance Solutions Partners with Clym to Enhance Merchants' Compliance and Website Accessibility, Empowering Businesses to Navigate Digital Regulations Seamlessly THE WOODLANDS, TX / ACCESSWIRE... ► Artikel lesen | |
02.10.24 | Eliem Therapeutics, Inc.: Eliem Therapeutics Announces Rebranding and Corporate Name Change to Climb Bio, Inc. | 177 | GlobeNewswire (Europe) | Name change to "Climb Bio" marks the Company's transition and focus on developing treatments for immune-mediated diseases Climb Bio will begin trading on Nasdaq under the trading symbol "CLYM" effective... ► Artikel lesen | |
25.09.24 | Pre-market Movers: Stitch Fix, Motorsport Games, Eliem Therapeutics, Banzai International, VS MEDIA | 800 | AFX News | BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 07.35 A.M. ET).In the Green Motorsport Games Inc. (MSGM) is up over 25% at... ► Artikel lesen | |
14.08.24 | Eliem Therapeutics, Inc.: Eliem Therapeutics Reports Second Quarter Financial Results | 107 | GlobeNewswire (Europe) | Eliem completed the acquisition of Tenet Medicines and concurrent $120 million private placement Eliem to host an Investor Day later in the year to provide an overview of budoprutug (previously referred... ► Artikel lesen | |
28.06.24 | Eliem Therapeutics, Inc.: Eliem Therapeutics Announces its Addition to the Russell 2000 and Russell 3000 Indexes | 230 | GlobeNewswire (Europe) | SEATTLE and CAMBRIDGE, United Kingdom, June 28, 2024 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM), announced today that the Company will be included in the Russell 2000® Index and the... ► Artikel lesen | |
27.06.24 | Eliem Therapeutics, Inc.: Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement | 482 | GlobeNewswire (Europe) | Eliem to focus on advancing TNT119, an anti-CD19 antibody designed to treat a broad range of autoimmune diseases, including systemic lupus erythematosus, immune thrombocytopenia and membranous nephropathy... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BIONTECH | 102,50 | +1,08 % | BioNTech-Aktie: Ein schnelles Ende! | News von Trading-Treff.de BioNTech schafft es derzeit einfach nicht, die negativen Stimmungen am Markt zu besiegen. Die Aktie verlor am Donnerstag rund 1,6 %. Damit ist der Wert wieder auf dem Weg in... ► Artikel lesen | |
CUREVAC | 2,808 | +0,14 % | CureVac-Aktie: Das wird zum Kracher! | News von Trading-Treff.de Eine erneut vernichtende Entwicklung nimmt nun die Aktie von CureVac. Das Papier hat am Donnerstag einen Abschlag in Höhe von -1,6% hinnehmen müssen. Damit ist die Aktie aktuell... ► Artikel lesen | |
MODERNA | 23,390 | -0,09 % | Moderna-Aktie mit leichten Kursgewinnen (23,7947 €) | Am US-amerikanischen Aktienmarkt liegt das Wertpapier von Moderna zur Stunde im Plus. Das Papier notiert gegenwärtig bei 27,05 US-Dollar. Der Anteilsschein von Moderna verzeichnet aktuell ein Kursplus... ► Artikel lesen | |
REGENERON PHARMACEUTICALS | 518,60 | 0,00 % | Regeneron Pharma Partners With FujiFilm Diosynth To Boost Capacity At $3 Bln Investment | WASHINGTON (dpa-AFX) - Regeneron Pharma, Inc. (REGN), a biotechnology company, on Tuesday announced a major expansion of its manufacturing capacity through a new agreement with FujiFilm Diosynth... ► Artikel lesen | |
EVOTEC | 7,298 | +1,11 % | EQS-News: Evotec SE stellt neue Strategie vor und gibt Ausblick für 2025 gestützt durch starkes Ergebnis im 4. Quartal 2024 | EQS-News: Evotec SE
/ Schlagwort(e): Jahresbericht
Evotec SE stellt neue Strategie vor und gibt Ausblick für 2025 gestützt durch starkes Ergebnis im 4. Quartal 2024
17.04.2025... ► Artikel lesen | |
TEMPUS AI | 51,04 | +2,97 % | Gemeinsam gegen Krebs: Tempus AI, AstraZeneca und Pathos AI entwickeln KI-Modell | CHICAGO, Illinois (IT-Times) - Das Diagnose-Technologie-Unternehmen Tempus AI hat heute bekannt gegeben, zusammen mit AstraZeneca und Pathos AI ein Foundation-Modell im Bereich der Onkologie zu entwickeln.... ► Artikel lesen | |
QIAGEN | 37,385 | -0,43 % | UBS stuft QIAGEN NV auf 'Neutral' | ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat die Einstufung für Qiagen bei einem Kursziel von 48 US-Dollar auf "Neutral" belassen. Die Ziele seien bestätigt worden, nähere Details seien... ► Artikel lesen | |
MINERALYS THERAPEUTICS | 13,530 | 0,00 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Announces Publication of Pivotal Phase 2 Advance-HTN Results in the New England Journal of Medicine (NEJM) | ||
TARSUS PHARMACEUTICALS | 49,990 | 0,00 % | Tarsus Pharmaceuticals, Inc: Tarsus to Present Several Scientific Abstracts Highlighting the Global Prevalence of Demodex Blepharitis and the Clinical Impact of XDEMVY at the American Society of Cataract and Refractive Surgery (ASCRS) 2025 ... | ||
NURIX THERAPEUTICS | 11,640 | 0,00 % | Nurix Therapeutics, Inc.: Nurix Announces FDA Clearance of IND Application for GS-6791/NX-0479 - a Novel IRAK4 Degrader for Inflammatory Conditions | Collaboration partner, Gilead Sciences, to begin Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) study in healthy volunteers in Q2 2025 GS-6791/NX-0479 has potential clinical... ► Artikel lesen | |
CG ONCOLOGY | 20,720 | 0,00 % | CG Oncology Inc.: CG Oncology Reports 2024 Year End Financial Results and Provides Business Updates | - Cretostimogene Monotherapy Demonstrated Sustained, Durable Complete Responses in High-Risk Bacillus Calmette Guérin (BCG)-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) - - Initiated... ► Artikel lesen | |
ADMA BIOLOGICS | 22,200 | +2,07 % | ADMA Biologics, Inc.: ADMA Biologics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update | FY 2024 Total Revenue of $426.5 Million, a 65% YoY Increase FY 2024 GAAP Net Income of $197.7 Million, Including an $84.3 Million Valuation Allowance Tax Benefit FY 2024 Adjusted EBITDA(1)... ► Artikel lesen | |
BICARA THERAPEUTICS | 15,480 | 0,00 % | Bicara wird aktualisierte Studiendaten auf ASCO-Tagung präsentieren | ||
HARMONY BIOSCIENCES | 28,910 | 0,00 % | JAZZ vs. HRMY: Which Neuroscience Drugmaker Is the Stronger Play? | ||
RECURSION PHARMACEUTICALS | 5,660 | +1,62 % | Recursion Pharmaceuticals: Recursion to Present Preliminary Clinical Data from the Ongoing Phase 1b/2 trial of REC-4881 in FAP at Digestive Disease Week 2025 |